154 related articles for article (PubMed ID: 18955485)
1. G6b-B inhibits constitutive and agonist-induced signaling by glycoprotein VI and CLEC-2.
Mori J; Pearce AC; Spalton JC; Grygielska B; Eble JA; Tomlinson MG; Senis YA; Watson SP
J Biol Chem; 2008 Dec; 283(51):35419-27. PubMed ID: 18955485
[TBL] [Abstract][Full Text] [Related]
2. An investigation of hierachical protein recruitment to the inhibitory platelet receptor, G6B-b.
Coxon CH; Sadler AJ; Huo J; Campbell RD
PLoS One; 2012; 7(11):e49543. PubMed ID: 23185356
[TBL] [Abstract][Full Text] [Related]
3. C-type lectin-like receptor-2 (CLEC-2) is a key regulator of kappa-carrageenan-induced tail thrombosis model in mice.
Yokomori R; Shirai T; Tsukiji N; Oishi S; Sasaki T; Takano K; Suzuki-Inoue K
Platelets; 2023 Dec; 34(1):2281941. PubMed ID: 38010137
[TBL] [Abstract][Full Text] [Related]
4. Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2, and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand.
Martin EM; Clark JC; Montague SJ; Morán LA; Di Y; Bull LJ; Whittle L; Raka F; Buka RJ; Zafar I; Kardeby C; Slater A; Watson SP
J Thromb Haemost; 2024 Jan; 22(1):271-285. PubMed ID: 37813196
[TBL] [Abstract][Full Text] [Related]
5. GPVI potentiation of platelet activation by thrombin and adhesion molecules independent of Src kinases and Syk.
Hughan SC; Hughes CE; McCarty OJ; Schweighoffer E; Soultanova I; Ware J; Tybulewicz VL; Watson SP
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):422-9. PubMed ID: 17110603
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of spleen tyrosine kinase at Y346 negatively regulates ITAM-mediated signaling and function in platelets.
Dangelmaier CA; Patchin M; Vajipayajula DN; Vari HR; Singh PK; Wright MN; Kostyak JC; Tsygankov AY; Kunapuli SP
J Biol Chem; 2023 Jul; 299(7):104865. PubMed ID: 37268160
[TBL] [Abstract][Full Text] [Related]
7. Treatment of congenital thrombocytopenia and decreased collagen reactivity in G6b-B-deficient mice.
Mazharian A; Maître B; Bornert A; Hennequin D; Lourenco-Rodrigues M; Geer MJ; Smith CW; Heising S; Walter M; Montel F; Walker LSK; de la Salle H; Watson SP; Gachet C; Senis YA
Blood Adv; 2023 Jan; 7(1):46-59. PubMed ID: 36269841
[TBL] [Abstract][Full Text] [Related]
8. GPVI signaling is compromised in newly formed platelets after acute thrombocytopenia in mice.
Gupta S; Cherpokova D; Spindler M; Morowski M; Bender M; Nieswandt B
Blood; 2018 Mar; 131(10):1106-1110. PubMed ID: 29295843
[TBL] [Abstract][Full Text] [Related]
9. Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B.
Vögtle T; Sharma S; Mori J; Nagy Z; Semeniak D; Scandola C; Geer MJ; Smith CW; Lane J; Pollack S; Lassila R; Jouppila A; Barr AJ; Ogg DJ; Howard TD; McMiken HJ; Warwicker J; Geh C; Rowlinson R; Abbott WM; Eckly A; Schulze H; Wright GJ; Mazharian A; Fütterer K; Rajesh S; Douglas MR; Senis YA
Elife; 2019 Aug; 8():. PubMed ID: 31436532
[TBL] [Abstract][Full Text] [Related]
10. Regulation of platelet activation and thrombus formation by reactive oxygen species.
Qiao J; Arthur JF; Gardiner EE; Andrews RK; Zeng L; Xu K
Redox Biol; 2018 Apr; 14():126-130. PubMed ID: 28888895
[TBL] [Abstract][Full Text] [Related]
11. CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development.
Finney BA; Schweighoffer E; Navarro-Núñez L; Bénézech C; Barone F; Hughes CE; Langan SA; Lowe KL; Pollitt AY; Mourao-Sa D; Sheardown S; Nash GB; Smithers N; Reis e Sousa C; Tybulewicz VL; Watson SP
Blood; 2012 Feb; 119(7):1747-56. PubMed ID: 22186994
[TBL] [Abstract][Full Text] [Related]
12. A structural basis for the inhibition of collagen-stimulated platelet function by quercetin and structurally related flavonoids.
Wright B; Moraes LA; Kemp CF; Mullen W; Crozier A; Lovegrove JA; Gibbins JM
Br J Pharmacol; 2010 Mar; 159(6):1312-25. PubMed ID: 20148891
[TBL] [Abstract][Full Text] [Related]
13. Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists.
Clark JC; Martin EM; Morán LA; Di Y; Wang X; Zuidscherwoude M; Brown HC; Kavanagh DM; Hummert J; Eble JA; Nieswandt B; Stegner D; Pollitt AY; Herten DP; Tomlinson MG; García A; Watson SP
Commun Biol; 2023 Apr; 6(1):376. PubMed ID: 37029319
[TBL] [Abstract][Full Text] [Related]
14. The structure of CLEC-2: mechanisms of dimerization and higher-order clustering.
Martin EM; Zuidscherwoude M; Morán LA; Di Y; García A; Watson SP
Platelets; 2021 Aug; 32(6):733-743. PubMed ID: 33819136
[TBL] [Abstract][Full Text] [Related]
15. TC21/RRas2 regulates glycoprotein VI-FcRγ-mediated platelet activation and thrombus stability.
Janapati S; Wurtzel J; Dangelmaier C; Manne BK; Bhavanasi D; Kostyak JC; Kim S; Holinstat M; Kunapuli SP; Goldfinger LE
J Thromb Haemost; 2018 Jun; ():. PubMed ID: 29883056
[TBL] [Abstract][Full Text] [Related]
16. Determination of the substrate specificity of protein-tyrosine phosphatase TULA-2 and identification of Syk as a TULA-2 substrate.
Chen X; Ren L; Kim S; Carpino N; Daniel JL; Kunapuli SP; Tsygankov AY; Pei D
J Biol Chem; 2010 Oct; 285(41):31268-76. PubMed ID: 20670933
[TBL] [Abstract][Full Text] [Related]
17. Experimental validation of computerised models of clustering of platelet glycoprotein receptors that signal via tandem SH2 domain proteins.
Maqsood Z; Clark JC; Martin EM; Cheung YFH; Morán LA; Watson SET; Pike JA; Di Y; Poulter NS; Slater A; Lange BMH; Nieswandt B; Eble JA; Tomlinson MG; Owen DM; Stegner D; Bridge LJ; Wierling C; Watson SP
PLoS Comput Biol; 2022 Nov; 18(11):e1010708. PubMed ID: 36441766
[TBL] [Abstract][Full Text] [Related]
18. Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs.
Babur Ö; Melrose AR; Cunliffe JM; Klimek J; Pang J; Sepp AI; Zilberman-Rudenko J; Tassi Yunga S; Zheng T; Parra-Izquierdo I; Minnier J; McCarty OJT; Demir E; Reddy AP; Wilmarth PA; David LL; Aslan JE
Blood; 2020 Nov; 136(20):2346-2358. PubMed ID: 32640021
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein VI oligomerization in cell lines and platelets.
Berlanga O; Bori-Sanz T; James JR; Frampton J; Davis SJ; Tomlinson MG; Watson SP
J Thromb Haemost; 2007 May; 5(5):1026-1033. PubMed ID: 17367493
[TBL] [Abstract][Full Text] [Related]
20. Low-dose Btk inhibitors selectively block platelet activation by CLEC-2.
Nicolson PLR; Nock SH; Hinds J; Garcia-Quintanilla L; Smith CW; Campos J; Brill A; Pike JA; Khan AO; Poulter NS; Kavanagh DM; Watson S; Watson CN; Clifford H; Huissoon AP; Pollitt AY; Eble JA; Pratt G; Watson SP; Hughes CE
Haematologica; 2021 Jan; 106(1):208-219. PubMed ID: 31949019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
